AbdulHussein Ali Hamid, Al-Taee Muataz Mohammed, Radih Zahra Abdul, Aljuboory Dhuha Salman, Mohammed Zainab Qasim, Hashesh Tabarak Sami, Riadi Yassine, Hadrawi Salema K, Najafi Masoud
Department of Pharmaceutics, College of Pharmacy, University of Al-Ameed, Karbala, Iraq.
Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq.
Biofactors. 2023 Jul-Aug;49(4):718-735. doi: 10.1002/biof.1944. Epub 2023 Mar 6.
Drug resistance is a hot topic issue in cancer research and therapy. Although cancer therapy including radiotherapy and anti-cancer drugs can kill malignant cells within the tumor, cancer cells can develop a wide range of mechanisms to resist the toxic effects of anti-cancer agents. Cancer cells may provide some mechanisms to resist oxidative stress and escape from apoptosis and attack by the immune system. Furthermore, cancer cells may resist senescence, pyroptosis, ferroptosis, necroptosis, and autophagic cell death by modulating several critical genes. The development of these mechanisms leads to resistance to anti-cancer drugs and also radiotherapy. Resistance to therapy can increase mortality and reduce survival following cancer therapy. Thus, overcoming mechanisms of resistance to cell death in malignant cells can facilitate tumor elimination and increase the efficiency of anti-cancer therapy. Natural-derived molecules are intriguing agents that may be suggested to be used as an adjuvant in combination with other anticancer drugs or radiotherapy to sensitize cancer cells to therapy with at least side effects. This paper aims to review the potential of triptolide for inducing various types of cell death in cancer cells. We review the induction or resistance to different cell death mechanisms such as apoptosis, autophagic cell death, senescence, pyroptosis, ferroptosis, and necrosis following the administration of triptolide. We also review the safety and future perspectives for triptolide and its derivatives in experimental and human studies. The anticancer potential of triptolide and its derivatives may make them effective adjuvants for enhancing tumor suppression in combination with anticancer therapy.
耐药性是癌症研究和治疗中的一个热门话题。尽管包括放疗和抗癌药物在内的癌症治疗可以杀死肿瘤内的恶性细胞,但癌细胞可以发展出多种机制来抵抗抗癌药物的毒性作用。癌细胞可能提供一些机制来抵抗氧化应激,并逃避免疫系统的凋亡和攻击。此外,癌细胞可能通过调节几个关键基因来抵抗衰老、焦亡、铁死亡、坏死性凋亡和自噬性细胞死亡。这些机制的发展导致对抗癌药物以及放疗产生耐药性。治疗耐药性会增加死亡率并降低癌症治疗后的生存率。因此,克服恶性细胞对细胞死亡的耐药机制可以促进肿瘤消除并提高抗癌治疗的效率。天然来源的分子是有趣的药物,可能被建议用作辅助药物,与其他抗癌药物或放疗联合使用,以使癌细胞对治疗敏感,同时副作用最小。本文旨在综述雷公藤甲素诱导癌细胞发生各种类型细胞死亡的潜力。我们综述了雷公藤甲素给药后对不同细胞死亡机制(如凋亡、自噬性细胞死亡、衰老、焦亡、铁死亡和坏死)的诱导或耐药情况。我们还综述了雷公藤甲素及其衍生物在实验和人体研究中的安全性和未来前景。雷公藤甲素及其衍生物的抗癌潜力可能使其成为与抗癌治疗联合增强肿瘤抑制作用的有效辅助药物。